Please assess the completion status of the following clinical trial:

Trial Title: The Role of Resistant Starch in COVID-19 Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* greater than 18 years of age~* COVID-positive status~* Being monitored in an outpatient setting at one of our study sites:~* Yale New Haven Hospital (YNHH)~* University of Michigan~* University of Minnesota~Exclusion Criteria:~* inflammatory bowel disease~* history of gastric bypass surgery~* active Clostridium difficile infection~* active participation in another COVID-19 interventional trial~* any physical or psychological condition that, in the opinion of the investigator, would pose unacceptable risk to the patient or raise concern that the patient would not comply with the protocol procedures.~* Reported allergy to starch~* Difficulty swallowing in order to prevent any aspiration risk~* Currently taking any IL-6 inhibitors such as Tocilizumab for any disease condition

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): Subjects will receive a dietary supplement containing resistant starch and be instructed to take 2 tablespoons (\~20 grams) twice daily for 14 days. Initially subjects will take 2 tablespoons once daily for the first three days prior to increasing to 2 tablespoons twice daily.
- Control (Type: PLACEBO_COMPARATOR): Subjects will receive a placebo starch, consisting of non resistant starch and be instructed to take 2 tablespoons (\~ 20 grams) twice daily for 14 days. Initially subjects will take 2 tablespoons once daily for the first three days.

Based on this trial design, predict the completion outcome and termination type (if applicable).